Evidence map›Paper›PMID 34578387›Full record

ArticleViruses2021

High Rate of Mutational Events in SARS-CoV-2 Genomes across Brazilian Geographical Regions, February 2020 to June 2021.

Ueric José Borges de Souza, Raíssa Nunes Dos Santos, Fabrício Souza Campos, Karine Lima Lourenço, Flavio Guimarães da Fonseca, Fernando Rosado Spilki, Corona-Ômica Br/McTi Network

Abstract readHistorical Article
In one paragraph

Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Community seroprevalence and risk factors for SARS-CoV-2 infection in different subpopulations in Vellore, India, and their implications for future prevention.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022
    Article
  13. Article
  14. Repurposing Antifungals for Host-Directed Antiviral Therapy?Pharmaceuticals (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ueric José Borges de SouzaLaboratório de Bioinformática e Biotecnologia, Campus de Gurupi, Universidade Federal do Tocantins, Gurupi 77402-970, Brazil.ORCID 0000-0003-1442-4771
Raíssa Nunes Dos SantosLaboratório de Bioinformática e Biotecnologia, Campus de Gurupi, Universidade Federal do Tocantins, Gurupi 77402-970, Brazil.ORCID 0000-0003-3388-890X
Fabrício Souza CamposLaboratório de Bioinformática e Biotecnologia, Campus de Gurupi, Universidade Federal do Tocantins, Gurupi 77402-970, Brazil.ORCID 0000-0002-5948-472X
Karine Lima LourençoLaboratório de Virologia Básica e Aplicada, Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil.
Flavio Guimarães da FonsecaLaboratório de Virologia Básica e Aplicada, Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil.ORCID 0000-0002-1416-8694
Fernando Rosado SpilkiLaboratório de Saúde Única, Feevale Techpark, Universidade Feevale, Av. Edgar Hoffmeister, 600, Zona Industrial Norte, Campo Bom 93700-000, Brazil.ORCID 0000-0001-5804-7045
Corona-Ômica Br/McTi NetworkLaboratório de Microbiologia Molecular, Universidade Feevale, Rodovia ERS-239, 2755, Prédio Vermelho, Piso 1, sala 103, Vila Nova, Novo Hamburgo 93525-075, Brazil.

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 404096/2020-4Financiadora de Estudos e Projetos 01.20.0029.000462/20
6 · The paper itself

Abstract

Brazil was considered one of the emerging epicenters of the coronavirus pandemic in 2021, experiencing over 3000 daily deaths caused by the virus at the peak of the second wave. In total, the country had more than 20.8 million confirmed cases of COVID-19, including over 582,764 fatalities. A set of emerging variants arose in the country, some of them posing new challenges for COVID-19 control. The goal of this study was to describe mutational events across samples from Brazilian SARS-CoV-2 sequences publicly obtainable on Global Initiative on Sharing Avian Influenza Data-EpiCoV (GISAID-EpiCoV) platform and to generate indexes of new mutations by each genome. A total of 16,953 SARS-CoV-2 genomes were obtained, which were not proportionally representative of the five Brazilian geographical regions. A comparative sequence analysis was conducted to identify common mutations located at 42 positions of the genome (38 were in coding regions, whereas two were in 5' and two in 3' UTR). Moreover, 11 were synonymous variants, 27 were missense variants, and more than 44.4% were located in the spike gene. Across the total of single nucleotide variations (SNVs) identified, 32 were found in genomes obtained from all five Brazilian regions. While a high genomic diversity has been reported in Europe given the large number of sequenced genomes, Africa has demonstrated high potential for new variants. In South America, Brazil, and Chile, rates have been similar to those found in South Africa and India, providing enough "space" for new mutations to arise. Genomic surveillance is the central key to identifying the emerging variants of SARS-CoV-2 in Brazil and has shown that the country is one of the "hotspots" in the generation of new variants.

Indexed as

Genome, ViralMutationBrazilCOVID-19Evolution, MolecularGenotypeHistory, 21st CenturyHumansModels, TheoreticalMutation RatePhylogenyPhylogeographyPublic Health SurveillanceSARS-CoV-2genome analysismathematical correlationSARS-CoV-2variants hotspotviral evolution

Identifiers

PMID34578387
PMCPMC8473193

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.